FDA staff raises concerns over data from J&J, Bristol's CAR-T therapies

The U.S. Food and Drug Administration's staff on Wednesday raised concerns that it was unclear if Johnson & Johnson and Bristol Myers Squibb's cancer cell therapies would benefit blood cancer patients when given as early treatments.